Helixmith Co., Ltd (KOSDAQ:084990)

Market Cap	279.04B +109.0%
Revenue (ttm)	3.74B -3.6%
Net Income	-5.27B
EPS	-114.50
Shares Out	46.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	598,258
Average Volume	456,466
Open	5,950.00
Previous Close	6,010.00
Day's Range	5,510.00 - 6,120.00
52-Week Range	2,115.00 - 8,940.00
Beta	1.18
RSI	48.98
Earnings Date	Mar 19, 2026

About Helixmith

Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease. The company al...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 38
• Stock Exchange: KOSDAQ
• Ticker Symbol: 084990

Financial Performance

In 2024, Helixmith's revenue was 4.97 billion, an increase of 18.38% compared to the previous year's 4.20 billion. Losses were -15.47 billion, -75.86% less than in 2023.